Sei Investments Co. Purchases 44,474 Shares of Enovis Corporation $ENOV

Sei Investments Co. lifted its holdings in Enovis Corporation (NYSE:ENOV) by 37.1% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 164,253 shares of the company’s stock after buying an additional 44,474 shares during the period. Sei Investments Co. owned approximately 0.29% of Enovis worth $3,737,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Arax Advisory Partners bought a new stake in Enovis during the fourth quarter worth $29,000. EverSource Wealth Advisors LLC grew its stake in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares during the period. Danske Bank A S bought a new position in Enovis in the 3rd quarter valued at $64,000. iSAM Funds UK Ltd purchased a new stake in shares of Enovis during the 3rd quarter valued at $80,000. Finally, Brown Brothers Harriman & Co. purchased a new stake in shares of Enovis during the 3rd quarter valued at $90,000. 98.45% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on ENOV. Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Evercore set a $32.00 price target on Enovis in a research report on Monday, July 6th. Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. BTIG Research lifted their price objective on Enovis from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday. Finally, BMO Capital Markets began coverage on shares of Enovis in a report on Wednesday, July 8th. They set an “outperform” rating and a $29.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Enovis has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Insider Transactions at Enovis

In related news, insider Oliver Engert bought 1,200 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was acquired at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the purchase, the insider directly owned 51,840 shares in the company, valued at $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders bought 4,200 shares of company stock worth $92,084. Corporate insiders own 2.90% of the company’s stock.

Enovis News Roundup

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q2 earnings exceeded expectations: Enovis reported adjusted EPS of $0.90, above the $0.83–$0.85 analyst estimates and up from $0.79 a year earlier. Revenue increased 3.2% year over year to $582.8 million, narrowly beating the $581.8 million consensus. Enovis Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Reconstructive business remained strong: Reconstructive sales grew 8% on a reported basis and 6% organically, helping drive total second-quarter sales growth of 3% reported and 5% organically. Management reaffirmed its full-year 2026 revenue, adjusted EBITDA, adjusted EPS and free-cash-flow-conversion targets. Enovis Announces Second Quarter 2026 Results
• Positive Sentiment: Analyst support increased: BTIG Research raised its Enovis price target to $40 from $39 and assigned a Buy rating, indicating substantial potential upside from recent trading levels. BTIG Raises Enovis Price Target
• Neutral Sentiment: 2026 guidance was reaffirmed: Enovis forecast revenue of approximately $2.3 billion to $2.4 billion and EPS of $3.52 to $3.73. The EPS range broadly brackets the $3.54 consensus estimate, offering limited evidence of a meaningful outlook increase.
• Negative Sentiment: Investors may have wanted stronger growth or guidance: Although profitability beat estimates, reported sales growth remained modest, and the company continues to report a negative net margin. Those factors may be overshadowing the quarterly beat and positive analyst action.

Enovis Trading Down 12.2%

Shares of ENOV stock opened at $26.50 on Friday. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of -1.33 and a beta of 1.34. The company’s fifty day simple moving average is $24.54 and its two-hundred day simple moving average is $23.95. Enovis Corporation has a 1 year low of $19.14 and a 1 year high of $34.28. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. The firm had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The business’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same period last year, the company earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts anticipate that Enovis Corporation will post 3.12 earnings per share for the current year.

Enovis Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.